Roche’s Alzheimer’s failure increases tension for Biogen - STAT

Roche’s Alzheimer’s failure increases tension for Biogen - STAT

STAT Plus: Roche’s Alzheimer’s failure increases tension for Biogen

By MATTHEW HERPER

NATIONAL INSTITUTE ON AGING, NIH

The news is not weighing on Roche's stock, but it is weighing on Biogen, which is betting its future on another beta-amyloid-targeting drug.

READ MORE